LifeAgain Insurance Solutions, a wholly owned subsidiary of Cardium Therapeutics, today announced its support of Life Insurance Awareness Month. Taking place during September, this campaign is sponsored by the Life and Health Insurance Foundation for Education (LIFE). LIFE’s aim is to help people take personal financial responsibility through the ownership of life insurance and other related insurance, including disability and long-term care insurance, to financially protect their loved ones.
Although life insurance rates for the traditional insurable population are at record lows, the percentage of U.S. households with coverage has steadily declined over the past 25 years—from 62 percent in 1985 to an all-time 50-year low of 44 percent in 2010. However, for cancer patients who really do “need life insurance,” their hands often are tied. Life insurance typically only becomes an option after five years of being cancer free. Even then, it can be an uphill battle depending on the type, stage, grade of the cancer, and the treatment plan.
In response, LifeAgain recently launched its BlueMetric™ Select term life insurance program for men with active localized prostate cancer. This program was developed based on LifeAgain’s Advanced Medical Data Analytics Platform Technology (ADAPT™). Prostate cancer is one of the most prevalent forms of cancer in the United States. Currently, men with elevated prostate-specific antigen (PSA) scores and active localized prostate cancer usually are considered uninsurable based on traditional underwriting standards. LifeAgain’s BlueMetric Select program was specifically designed to assist life insurance companies to provide eligible men with term life insurance coverage following a cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.
Additional information about the BlueMetric Select Program is available at www.lifeagain.com
Let us hear your thoughts below:
